EN 
TH > OUR NETWORK
Partners
SICRES maintains clinical trial agreements with the leading research organizations Parexel, Novotech, DNDi, NCGM, and GreenLight. This relationship enables SICRES to conduct cutting edge research with global impacts. These research organizations recognize that SICRES offers a large patient population, modern medical facilities, lower trial costs and a strategic gateway to Asian markets.
- Green light clinical
- The Drugs for Neglected Diseases initiative (DNDi)
- Global Antibiotic Research and Development Partnership (GARDP)
- Parexel
- Novotech
- IQVIA
- Government Pharmaceutical Organization (GPO)
- University of California, Los Angeles (UCLA)
- The National Center for Global Health and Medicine (NCGM)
- Oregon Health & Science University (OHSU)
- ICON Clinical Research (Thailand) Limited
- PRA
- PPD
- ClinActis Pte Ltd
Dr. Sasi Suda
Founder & CEO, GreenLight Clinical
Partners with us
SICRES pioneers to improve the health of our community and the world by answering important questions that advance clinical practice through conducting high-quality clinical research and communicating the results to clinicians, patients, and policymakers.
As African proverb said “If you want to go fast, go alone. If you want to go far, go together”.
At SICRES, we have focus on our mission to transform patient care and improve human health. Thus, in resource limited area, we team up with international and national institutes, organisations, and companies and bring together members and partners with aligned goals to generate knowledge in improvement of health.
Contact us at [email protected]h or +66 2 414 1899.
Sponsors / Funders
- ALexion Pharmaceutical Inc.
- Alivio Therapeutics
- ALLERGAN THAILAND, LLC
- AnaptysBio Inc.
- Apexcela Co. Ltd.
- Ascendant Biotech Corporation
- Asklepios Biopharmaceuticals, Inc.
- Astellas Pharma Inc.
- AstraZeneca (Thailand) Ltd.
- Auris Medical AG
- Bayer Thai Company Limited
- Beiersdorf (Thailand) Co., Ltd.
- BLACKMORES LIMITED
- Boehringer Ingelheim Singapore
- Canadian/Toronto based HV study
- Checkpoint Therapeutics, Inc.
- Cidara Therapeutics, Inc
- Cipla Ltd
- Cubist Pharmaceuticals
- Dutch Mill Co., Ltd.
- EU Biotech
- F2G Biotech GmbH
- Ferrokin
- F-Hoffman La Roche (Thailand) Ltd.
- GlaxoSmithKline (Thailand) Limited
- Great Eastern Drug Co., Ltd
- Inovio Pharmaceuticals, Inc.
- Insmed Incoporated
- Instylla Inc.
- Janssen-Cilag Ltd.,
- LG Life Sciences Ltd.
- Medi Us Co.,Ltd.
- MERCK & Co Inc
- Millennium Pharmaceuticals Inc.
- MSD (THAILAND) LTD.,
- National Center for Global Health and Medicine (NCGM)
- Nodthera
- Novartis (Thailand) Ltd.
- PCI Biotech
- Pfizer Thailand Ltd.
- Pharmaland (1982) Co.,Ltd.
- PT Kalbe Genexine Biologics
- Puma Biotechnology
- Rajburi Sugar Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- Ripple Therapeutics Corporation
- Roche (Thailand) Ltd.
- S.C. Artistry Co., Ltd.
- Sideris Pharmaceuticals, Inc
- Sillajen Inc.
- TOLMAR IInc.
- UCB Japan Co. Ltd.
- UK based biotech
- สถาบันวิจัยระบบสาธารณสุข (Health systems Research Institute)
